切换至 "中华医学电子期刊资源库"
高级检索
中华关节外科杂志(电子版)

中华关节外科杂志(电子版) ›› 2020, Vol. 14 ›› Issue (05) : 572 -577. doi: 10.3877/cma.j.issn.1674-134X.2020.05.009

所属专题： 文献；

临床论著

利伐沙班预防全膝关节置换术后深静脉血栓效果
柏正文1, 沈惠良1,†(), 安帅1   
  1. 1. 100053　北京，首都医科大学宣武医院
  • 收稿日期:2018-06-16 出版日期:2020-10-01
  • 通信作者: 沈惠良

Effect and complications of rivaroxaban in preventing deep venous thrombosis after total knee arthroplasty

Zhengwen Bai1, Huiliang Shen1,†(), Shuai An1   

  1. 1. Department of orthopedics, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
  • Received:2018-06-16 Published:2020-10-01
  • Corresponding author: Huiliang Shen
  • About author:
    Corresponding author: Shen Huiliang, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

柏正文, 沈惠良, 安帅. 利伐沙班预防全膝关节置换术后深静脉血栓效果[J]. 中华关节外科杂志(电子版), 2020, 14(05): 572-577.

Zhengwen Bai, Huiliang Shen, Shuai An. Effect and complications of rivaroxaban in preventing deep venous thrombosis after total knee arthroplasty[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2020, 14(05): 572-577.

目的

探讨为防止人工全膝关节置换术后深静脉血栓的形成及相关并发症应用利伐沙班的治疗价值。

方法

选取自2016年7月至2017年12月因膝关节骨关节炎于首都医科大学宣武医院骨科关节组行人工全膝关节置换术的患者，按照随机对照的原则抽取作为研究对象。排除有凝血功能障碍、血栓栓塞性病史或出血性病史，共84例患者，分为实验组和对照组各42例。实验组患者在术后给予利伐沙班抗凝治疗，对照组患者在术后给予依诺肝素抗凝治疗。比较两组患者术后深静脉血栓形成、肺栓塞及出血并发症(切口瘀斑、出血事件)的发生率，比较两组患者术后血液学指标的差异，比较两组患者引流量、输血量等相关指标。计量资料采用独立样本t检验；计数资料采取卡方检验。

结果

实验组患者术后早期深静脉血栓形成与对照组相比差异无统计学意义(χ2＝0.933，P>0.05)，两组患者均未发生肺栓塞；实验组早期出血并发症事件多于对照组(χ2＝6.574，P<0.05)。而两组患者术后血红蛋白、血小板、活化的部分凝血活酶时间、纤维蛋白原、D-二聚体相比差异均无统计学意义(P>0.05)；两组患者术后的引流量基本相同，两组的输血量、总失血量、隐性失血量相比均无统计学意义(P>0.05)。

结论

人工全膝关节置换术后应用利伐沙班作为抗凝药物，提供了抗凝治疗的便捷性，但其相关的出血并发症略高于依诺肝素，临床工作中可考虑分阶段使用以使得患者的受益最大化。

关键词: 利伐沙班, 依诺肝素, 关节成形术, 置换, 膝, 静脉血栓形成, 手术后并发症
Objective

To investigate the value of rivaroxaban in the treatment of deep venous thrombosis(DVT) and related complications after total knee arthroplasty.

Methods

Eighty-four patients of total knee arthroplasty due to knee osteoarthritis in Xuanwu Hospital from July 2016 to December 2017 were selected and randomly divided into experimental group (n =42) and the control group (n =42), the patients with coagulation dysfunction, thromboembolic history and bleeding history were excluded. The experimental group were given rivaroxaban anticoagulant therapy, while the control group were given enoxaparin anticoagulant therapy after the operation. The incidence of postoperative DVT, pulmonary embolism and bleeding complications (incision ecchymosis, bleeding events) were compared, and the differences of hematological indexes between the two groups were compared. The drainage volume, blood transfusion volume and other related indicators were compared between the two groups. The measurement data were analyzed by independent t test, chi-square test was used for count data.

Results

There was no statistically significant difference between the experimental group and the control group in early DVT incidence(χ2=0.933, P>0.05). No pulmonary embolism occured in the two groups, while the complications of early hemorrhage in the experimental group were higher than the control group (χ2=6.574, P<0.05). There was no statistically significant difference in hemoglobin, platelet, activated partial thromboplastin time, fibrinogen or D-dimer between the two groups (P>0.05). The drainage volume of the two groups was basically the same, and no statistically significant difference was found in the blood transfusion volume, total blood loss or hidden blood loss of the two groups (P>0.05).

Conclusion

Rivaroxaban as an anticoagulant after total knee arthroplasty provides the convenience of anticoagulant therapy, but its related bleeding complications are slightly higher than that of enoxaparin.

Key words: Rivaroxaban, Enoxaparin, Arthroplasty, replacement, knee, Venous thrombosis, Postoperative complications
表1 各组治疗前后各时间观察点WOMAC评分比较[分，(±s)]
一般项目 实验组 对照组 统计值 P值
例数 42 42    
年龄[岁，(±s)] 70±7 71±8 t＝0.260 >0.05
性别(例)        
男 4 7 χ2＝0.941 >0.05
女 38 35    
身高[cm，( ±s)] 158±7 159±7 t＝0.596 >0.05
体重[kg，( ±s)] 69±11 68±10 t＝0.414 >0.05
BMI[kg/m2，( ±s)] 27±3 27±4 t＝0.583 >0.05
手术侧别(例)        
左 17 20 χ2＝0.435 0.510
右 25 22    
手术史(例)        
有 13 10 χ2＝0.539 >0.05
无 29 32    
术前DVT(例)        
有 2 1 χ2＝0.346 >0.05
无 40 41    
表2 两组行TKA患者术后早期深静脉血栓形成、肺栓塞及出血并发症比较
组别 例数 术后早期DVT 术后早期PE 出血并发症
发生 未发生 发生 未发生 切口瘀斑 出血事件
实验组 42 14 28 0 42 10 2
对照组 42 10 32 0 42 2 1
χ2值   0.933 - 6.574
P值   >0.05 - <0.05
表3 两组患者术后血液学指标的比较(±s)
组别 例数 HB(g/L) PLT(109/L) APTT(s) FIB(mg/dl) D-D(ng/ml)
实验组 42 98.7±11.5 242.5±52.6 43.7±6.1 5.4±0.7 3.0±1.6
对照组 42 100.6±10.4 246.3±69.5 43.1±5.5 5.4±0.9 3.0±1.3
t值   0.973 0.298 0.422 0.249 0.022
P值   >0.05 >0.05 >0.05 >0.05 >0.05
表4 两组引流量、输血量、隐性失血等相关指标的比较(±s)
组别 引流量(ml) 输血量(ml) 总失血量(ml)
实验组 64±70 8±46 1 073±188
对照组 67±63 20±71 1 094±195
t值 0.260 0.927 0.500
P值 >0.05 >0.05 >0.05
[1]
Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141(2 Suppl): e278S-e325S.
[2]
Quinlan DJ, Eikelboom JW, Dahl OE, et al. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery[J]. J Thromb Haemost, 2007, 5(7): 1438-1443.
[3]
Howie C, Hughes H, Watts AC. Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study[J]. J Bone Joint Surg Br, 2005, 87(12): 1675-1680.
[4]
Sheth NP, Lieberman JR. Della valle CJ.DVT prophylaxis in total joint Reconstruction[J]. Orthopedic Clinics of North America, 2010, 41(2): 273-280.
[5]
Johanson NA, Lachiewicz PF, Lieberman JR, et al. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty[J]. J Am Acad Orthop Surg, 2009, 17(3): 183-196.
[6]
Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial[J]. Lancet, 2009, 373(9676): 1673-1680.
[7]
Baxter GM, Mckechnie S, Duffy P. Colourdoppler ultrasound in deep venous thrombosis: a comparison with venography[J]. Clin Radiol, 1990, 42(1): 32-36.
[8]
Kreutzer L, Minami C, Yang A．Preventing venous thromboembolism after surgery[J/OL]．JAMA, 2016, 315(19)：2136. doi：10.1001/jama.2016.1457.
[9]
Jacobs JJ, Mont MA, Bozic KJ, et al. American academy of orthopaedic surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty[J]. J Bone Joint Surg Am, 2012, 94(8): 746-747.
[10]
Friedman RJ. Optimal duration of prophylaxis for venous thromboembolism following total hip arthroplasty and total knee arthroplasty[J]. J Am Acad Orthop Surg, 2007, 15(3): 148-155.
[11]
Colleoni JL, Ribeiro FN, Mos P, et al. Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin vs. rivaroxaban[J]. Rev Bras Ortop, 2018, 53(1): 22-27.
[12]
Mao YC, Chen ST, Chen CH, et al. Rivaroxaban in preventing venous thromboembolism after arthroplastic surgery in Taiwan[J]. Kaohsiung J Med Sci, 2015, 31(10): 534-539.
[13]
Yong BC, Jun DZ, Hui S, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials[J]. Eur J Clin Pharmacol, 2010, 66(11): 1099-1108.
[14]
Feng W, Wu K, Liu Z, et al. Oral direct factor Ⅹa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis[J]. Thromb Res, 2015, 136(6): 1133-1144.
[15]
Geerts WH，Bergqvist D, Pineo GF. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2008, 133(6)：3815-4535.
[16]
Autar R. Nice guidelines on reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients undergoing surgery[J]. J Orthop Nurs, 2007, 11(3/4): 169-176.
[17]
Turun S, Banghua L, Yuan Y, et al. A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement[J]. Thromb Res, 2011, 127(6): 525-534.
[18]
Colwell CJ, Berkowitz SD, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study[J]. J Thromb Haemost, 2003, 1(10): 2119-2130.
[19]
Strebel N, Prins M, Agnelli G, et al. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery？[J]．Arch Intern Med, 2002，162(13)：1451-1456.
[20]
李虎，王健，史占军．骨科大手术应用抗凝药物的风险及并发症[J/CD]．中华关节外科杂志(电子版)，2013，7(1)：97-100.
[21]
Agnelli G, Bergqvist D, Dahl O, et al. Letter 3: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344)[J]. Br J Surg, 2006, 93(3): 375-376.
[22]
Jameson SS, Rymaszewska M, Hui AC, et al. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty[J]. J Bone Joint Surg Am, 2012, 94(17): 1554-1558.
[23]
EINSTEIN-PE Investigators, Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism[J]. N Engl J Med, 2012, 366(14): 1287-1297.
[24]
Macmanus KT, Velchik MG, Alavi, et al. Non-invasive assessment of postoperative bleeding in TKA patients with Tc-99m RNCs[J]. J Nucl Med, 1987, 28(1): 565-569
[25]
Sindali K, Rose B, Soueid H, et al. Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing[J]. Eur J Orthop Surg Traumatol, 2013, 23(4): 481-486.
[1] 林文, 王雨萱, 许嘉悦, 王矜群, 王睿娜, 何董源, 樊沛. 人工关节置换登记系统的研究进展[J]. 中华关节外科杂志(电子版), 2023, 17(06): 834-841.
[2] 陈山林, 魏绮珮, 刘畅. 腕关节假体：路在何方？[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 469-475.
[3] 吴香敏, 吴鹏. 超声引导下收肌管阻滞联合腘动脉与膝关节后囊间隙阻滞在老年患者全膝关节置换术中的应用效果[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 516-522.
[4] 黄应雄, 叶子, 蒋鹏, 詹红, 姚陈, 崔冀. 急性肠系膜静脉血栓形成致透壁性肠坏死的临床危险因素分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 413-421.
[5] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[6] 逄世江, 黄艳艳, 朱冠烈. 改良π形吻合在腹腔镜全胃切除消化道重建中的安全性和有效性研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 66-69.
[7] 杨体飞, 杨传虎, 陆振如. 改良无充气经腋窝入路全腔镜下甲状腺手术对喉返神经功能的影响研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 74-77.
[8] 陈大敏, 曹晓刚, 曹能琦. 肥胖对胃癌患者手术治疗效果的影响研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 651-653.
[9] 陈垚, 徐伯群, 高志慧. 改良式中间上入路根治术治疗甲状腺癌的有效性安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 619-622.
[10] 潘冰, 吕少诚, 赵昕, 李立新, 郎韧, 贺强. 淋巴结清扫数目对远端胆管癌胰十二指肠切除手术疗效的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 608-612.
[11] 崔佳琪, 吴迪, 陈海艳, 周惠敏, 顾元龙, 周光文, 杨军. TACE术后并发肝脓肿的临床诊治分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 688-693.
[12] 中华医学会骨科分会关节学组. 中国髋、膝关节置换日间手术围手术期管理专家共识[J]. 中华老年骨科与康复电子杂志, 2023, 09(06): 321-332.
[13] 邱红生, 林树体, 梁朝莹, 劳世高, 何荷. 模拟现实步态训练对膝关节前交叉韧带损伤的功能恢复及对跌倒恐惧的影响[J]. 中华老年骨科与康复电子杂志, 2023, 09(06): 343-350.
[14] 付庆鹏, 邓晓强, 高伟, 姜福民, 范永峰, 吴海贺, 齐岩松, 包呼日查, 徐永胜. 新型股骨测量定位器在全膝关节置换术中的临床应用[J]. 中华临床医师杂志(电子版), 2023, 17(9): 980-987.
[15] 李岩松, 李涛, 张元鸣飞, 李志鹏, 周谋望. 头戴式虚拟现实设备辅助全膝关节置换术后康复的初步研究[J]. 中华临床医师杂志(电子版), 2023, 17(06): 676-681.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号